Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-1.22 · Revenue $1.01M · 2 analysts
Est. EPS $-1.10 · Revenue $11.26M · 2 analysts
Est. EPS $-5.55 · Revenue $10.38M · 3 analysts
Est. EPS $-1.40 · Revenue $1.59M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $10.0M | +100.0% | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-377.7M | -140.6% | -37.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +100.0% | +103.7% | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -2113.8% | +35.5% | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -3777.4% | -20.3% | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-172.4M | -43.9% | +23.9% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -1723.5% | +28.1% | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 33.0% | +10187.3% | +50.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 5.61x | -9.8% | -16.8% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $383.6M | +3.7% | -6.2% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -8.44 vs -4.12 | -104.8% | -1.77 vs -1.12 | -57.7% |
| Revenue Surprise | $10.0M vs $18.0M | -44.4% | $1.0M vs $15.0M | -93.3% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Oliger Christy J. | director | Stock Option (Right to Buy) | A | 37,000 | $31.98 |
| Sep 1, 2026 | Oliger Christy J. | director: | — | — | 0 | — |
| Jun 15, 2026 | Nunn Jason Raleigh | director | Stock Option (Right to Buy) | A | 18,500 | $18.71 |
| Jun 15, 2026 | Lu Hongbo | director | Stock Option (Right to Buy) | A | 18,500 | $18.71 |
| Jun 15, 2026 | MOULDER LEON O JR | director, officer: See Remarks | Stock Option (Right to Buy) | A | 500,000 | $18.71 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Leon Oliver Moulder Jr. | Founder, CEO & Chairman | USD 891,800 | Male | 1957 | Active |
Joseph L. Farmer | Chief Operating Officer & President | USD 877,500 | Male | 1972 | Active |
Jennifer A. Fox | Chief Business Officer & Chief Financial Officer | USD 856,021 | Female | 1972 | Active |
Lisa von Moltke | Head of Research & Development and Chief Medical Officer. | USD 759,567 | — | 1959 | Active |
Caroline Chevalier | Chief Administrative Officer | — | Female | — | Active |
Jeffrey Held | Chief Legal Officer | — | Male | 1969 | Active |
Heinrich Schlieker | Chief Technical Officer | — | — | — | Active |
Haley Laken | Chief Scientific Officer | — | — | — | Active |
Bank of America Corp DE boosted its position in shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) by 723.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 388,347 shares of the company's stock after buying an additional 341,187 shares during the period.
WALTHAM, Mass., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on August 17, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted an aggregate of 11,000 restricted stock units of the Company's common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees' entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - - New study data confirm bioequivalence of obexelimab single-dose prefilled autoinjector pen compared to prefilled syringes - - Obexelimab global Phase 2 SunStone SLE trial topline results expected in Q4 2026 - - ZB021 (oral IL-17AA/AF inhibitor) dosing ongoing in Phase 1 trial; initial clinical data expected by year-end - - Four Orelabrutinib abstracts accepted for poster presentation at MSToronto 2026 - - Expanded Board of Directors with the appointment of Christy Oliger, who brings more than 30 years of global biopharmaceutical commercial and operating experience - - CFO to transition to Strategic Advisor to the Board Chair at the end of September - - Cash, cash equivalents and investments of $673.9 million as of June 30, 2026 - WALTHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today reported financial results for the quarter ended June 30, 2026, and provided recent corporate updates.
Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) and Arcturus Therapeutics (NASDAQ: ARCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability. Earnings and Valuation This table compares Zenas
WALTHAM, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on July 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 35,750 shares of the Company's common stock (“Stock Options”) and an aggregate of 79,050 restricted stock units of the Company's common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees' entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
